A study reveals that the APOE3-R136S mutation delays Alzheimer’s disease by inhibiting the cGAS-STING immune pathway. This mutation suppresses inflammation in brain-resident immune cells, offering ...

The scientists showed that the mutation inhibits the cGAS-STING pathway, an innate immune signaling cascade that is abnormally activated in Alzheimer’s and other neurodegenerative diseases.

Despite the significance of immune checkpoint inhibitors (ICIs) in solid tumor treatment, identifying ICI-sensitive populations remains a challenge. Mutations in DNA damage response (DDR) pathway ...

The planned phase 1b/2 clinical trial plans to evaluate LP-184 in advanced NSCLC patients with KEAP1 and/or STK11 mutations and low expression of PD-L1 in combination with the immune checkpoint ...

Using genetic analysis, Duh and colleagues identified a mutation in the KEAP1 gene in horses, donkeys, and zebras. This mutation introduced a stop codon, or a sequence in the genetic code that is the ...

They found that mutations in the STK11 and KEAP1 genes were linked to a less favorable tumor environment, often referred to as a "cold" microenvironment.

The TRITON study stems from an exploratory analysis of the POSEIDON trial, which looked at how the presence of STK11 and/or KEAP1 and/or KRAS mutations may affect treatment for nonsquasmous NSCLC ...

Davidson's previous research found that tumors arising from a KEAP1 mutation are extremely sensitive to deprivation of glutamine, an amino acid cells need for several essential processes.

We summarize drug resistance pathways such as the KEAP1/Nrf2 pathway MAPK pathway, and NF-κB pathway. Also, we analyze the limitations and conditions for the application of genome-wide CRISPR/Cas9 ...